Elsevier

Metabolism

Volume 36, Issue 10, October 1987, Pages 949-952
Metabolism

The dyslipoproteinemia of anabolic steroid therapy: Increase in hepatic triglyceride lipase precedes the decrease in high density lipoprotein2 cholesterol

https://doi.org/10.1016/0026-0495(87)90130-2Get rights and content
Under a Creative Commons license
open archive

Abstract

Administration of the androgenic anabolic steroid, stanozolol, is associated with decreased high density lipoprotein (HDL) cholesterol (primarily due to decreased HDL2 cholesterol) and increased levels of postheparin plasma hepatic triglyceride lipase (HTGL) activity. Since HTGL appears to play a role in HDL metabolism, we examined the temporal relationship between these changes. HDL cholesterol remained stable during the first two days of stanozolol administration, but decreased 14% (P < .01) by the third day and 39% (P < .01) by the seventh day of stanozolol. HDL2 cholesterol paralleled the total HDL cholesterol level and remained stable for the first two days, but decreased 22% (P < .01) after three days and 71% (P < .01) after seven days of stanozolol. In contrast, HTGL increased 62% (P < .001) during the first day, 161% (P < .001) with two days, 230% (P < .001) with three days of stanozolol administration, and remained elevated thereafter. Thus, during stanozolol administration HTGL increased dramatically and clearly before any change in HDL or HDL2 cholesterol.

Cited by (0)

Supported in part by NIH grants HL22381, HL22607, HL32474, HL30157, HL30193, CRC-RR-37, and a Grant-in-Aid from the American Heart Association of Washington.

1

Dr Haffner was supported by Training Grant HL07028.